跳至主要内容
临床试验/NL-OMON26131
NL-OMON26131已完成不适用

Pediatric Microdosing midazolam: elucidating age-related changes in oral drug absorption

Erasmus Medical Center0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age 0 to 6 years inclusive - At least 36 weeks of post conceptual age or bodyweight >2,5kg - Intravenous or intra-arterial access for blood sampling in place - Receiving midazolam IV - Parental informed consent

排除标准

  • Anticipated death in 48 hours - No informed consent - ECMO treatment - Circulatory failure: receiving more than 1 vasopressor or increase of vasopressor drug dose in the last 6 hours. - Chronic liver cirrhosis or chronic renal failure - Renal disorders: Estimated risk for kidney injury or failure at least ‘risk for renal dysfunction’ according to pRIFLE criteria - Hepatic failure: >2SD in age appropriate liver enzyme measurement (ASAT and ALAT) - Gastrointestinal disorderse - Use of co-medication known to affect midazolam metabolism (according to the Farmacotherapeutische Kompas, www.fk.cvz.nl, and Micromedex)

研究者

相似试验